CAJ | 학술논문

目的：评估阿仑膦酸钠对芳香化酶抑制剂(ais)引起的绝经后乳腺癌患者骨丢失的疗效。方法利用双能 X 线骨密度仪对226例接受芳香化酶抑制剂的绝经后乳腺癌妇女进行腰椎正位(l1-l4)、左侧股骨颈以及左侧全髋的骨密度(BMd)测定,同时测定292例同年龄段的正常女性的腰椎正位(l1-l4)、左侧股骨颈以及左侧全髋的 BMd。其中128例乳腺癌伴有骨量减少(取 t<-1.5)的患者接受了阿仑膦酸钠治疗6个月，6个月后检测接受治疗的患者的三个部位骨密度。结果接受芳香化酶治疗的乳腺癌患者的腰椎骨密度低于同年龄段的正常女性，两组间有统计学差异(P<0.05)。接受阿仑膦酸钠治疗患者的 BMd 较治疗前提高,治疗前后有统计学差异(P<0.05)。结论芳香化酶抑制剂对乳腺癌患者的骨密度具有负面影响，阿仑膦酸钠对接受芳香化酶抑制剂治疗的绝经后乳腺癌患者可以提高骨密度，降低骨质疏松和骨折的风险。
목적：평고아륜련산납대방향화매억제제(ais)인기적절경후유선암환자골주실적료효。방법이용쌍능 X 선골밀도의대226례접수방향화매억제제적절경후유선암부녀진행요추정위(l1-l4)、좌측고골경이급좌측전관적골밀도(BMd)측정,동시측정292례동년령단적정상녀성적요추정위(l1-l4)、좌측고골경이급좌측전관적 BMd。기중128례유선암반유골량감소(취 t<-1.5)적환자접수료아륜련산납치료6개월，6개월후검측접수치료적환자적삼개부위골밀도。결과접수방향화매치료적유선암환자적요추골밀도저우동년령단적정상녀성，량조간유통계학차이(P<0.05)。접수아륜련산납치료환자적 BMd 교치료전제고,치료전후유통계학차이(P<0.05)。결론방향화매억제제대유선암환자적골밀도구유부면영향，아륜련산납대접수방향화매억제제치료적절경후유선암환자가이제고골밀도，강저골질소송화골절적풍험。
Objective: to evaluate the effect of alendronate on the bone loss caused by aromatase inhibitors (aromatase inhibitors, ais) in patients with breast cancer(Bc) after menopause. Methods: BMd of the lumbar,left femoral neck,andthe total hip of 226 chinese postmenopausal women with breast cancer (Bc) were assessed using dual energy X-ray absorptiometry.simultaneous,to determinate the BMd of 292 normal women in the same age among those Bc patients, 128 patients were treated with alendronate, then testing the BMd of patients who received the treatment after 6 months. Results: BMd of the lumbar of patients treatedwith ais was significantly lower than those in control group (P<0.05).for patients receiving alendronate the BMd were higher than those before treatment (P<0.05) Conclusions: ais negatively affect BMd of postmenopausal women with Bc.alendronate improves bone density of menopause after receiving aromatase inhibitors for the treatment of breast cancer patients, reduce the risk of osteoporosis and fractures.